A Study of LY2127399 in Rheumatoid Arthritis

Inclusion Criteria:

- Diagnosis of adult onset RA disease according to revised 1987 American Rheumatism
Association (ARA) criteria and currently have a documented history of positive for
rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP Ab)
and have moderately to severely active RA despite ongoing methotrexate (MTX) therapy

- Have active RA defined as the presence of at least 8/68 tender and at least 8/66
swollen joints, as determined by the tender joint count and swollen joint count
assessment forms

- Have a screening C-reactive protein (CRP) measurement greater than 1.2 times upper
limit of normal or erythrocyte sedimentation rate (ESR) greater than 28
millimeters/hour (mm/hr)

- Have a clinically inflamed joint suitable for synovial biopsy procedure

Exclusion Criteria:

- Have used an unstable dose of non-steroidal anti-inflammatory drugs (NSAIDs) within 6
weeks prior to baseline

- Have used oral corticosteroids at average daily doses of >10 milligrams/day (mg/day)
of prednisone or its equivalent within 6 weeks prior to baseline

- Have received any parenteral corticosteroid injection within 6 weeks of baseline

- Have used other disease-modifying anti-rheumatic drugs (DMARDs) other than MTX,
hydroxychloroquine, and/or sulfasalazine in the 8 weeks prior to baseline